SerbinCreative

(805) 963-0439 | Toll-Free (800) 876-6425

www.serbincreative.com LA / NY / UK

Tivantinib®: MET receptor and HGF ligand 

Prev Next
Previous

Legal-Eye Tamponade

medical illustration of PowerPoint images and design for pharmaceutical method-of-action of Tivantinib, designed to block the activity of a molecule known as c-Met that plays multiple key roles in human cancer.
Next medical illustration of Part of a series; E-learning and booth graphics for therapeutic monoclonal antibody Daclizumab (Zenapax®) — Showing blockage of IL-2 receptor target. Drug's mechanism of action graphics at cellular level for pharmaceutical project. Keywords: molecular biology, cellular biology, histology, pharmacology, virology, disease management; multiple sclerosis

Daclizumab— Blockage of dendritic cell receptor

PowerPoint images and design for pharmaceutical method-of-action of Tivantinib, designed to block the activity of a molecule known as c-Met that plays multiple key roles in human cancer.

Keywords: Airbrush, Color, Design, Information Graphics, Education, Allergy / Immunology, Biology, Biotechnology, Cell biology / Histology, Disease Management, Endocrinology / Metabolic, Molecular Biology, Pharmacology

© Mica Duran